Home
Charts
Search
Watchlist
Products
All IPOs
₹35 - 35
Vijaypd Ceutical Ltd
RetailIPOSME
₹35 - 35
We are engaged in the business of distribution and supply within the pharmaceutical and consumer goods sectors, offering a comprehensive range of services. Our roles include being representatives, dealers, agents, stockists, suppliers, traders, and packers. We offer a wide range of products serving both the pharmaceutical and wellness industries, as well as the fastmoving consumer goods (FMCG) market. Our pharmaceutical and wellness product range includes medicines such as injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, and liquid oral formulations. We also supply vitamins, hormones, enzymes, wellness tonics, serums, and diagnostic test kits. In the FMCG segment, we provide personal care and toiletry products, including soaps, sanitizers, and baby care items. Additionally, we deal in ayurvedic products, cosmetics, food products, dental products, and crude drugs.
Lot4,000Min Invest₹2,80,000Face Value₹10Issue Size₹19 CrFresh Issue₹19 CrListing Price₹35CMP₹83
Timeline
29 Sept
Bidding opens
1 Oct
Bidding closes
3 Oct
Allotment
6 Oct
Refund & demat credit
7 Oct
Listing
Subscription
Subscription opens once dates are announced
Reports
Offer Details
Terms
Issue Size₹19 Cr0.55 Cr shares
Fresh Issue₹19 Cr
Face Value₹10
Lot Size4,000 shares
ReservationNII 50% · RETAIL 50%
Application Sizes
Retail₹2,80,0001-1 lots
sNII₹2,80,000from 2 lots
bNII₹11,20,000from 8 lots
Managers & Registrar
Lead ManagerSmart Horizon Capital Advisors Private Limited
RegistrarKFin Techologies Ltd
Ownership & Proceeds
Shareholding
CategoryPre IPOPost IPOPromoter Group78.31%56.25%Public21.69%43.75%
Objects of the Issue
- Funding of capital expenditure requirements of our company towards the construction of Pharmaceutical API/ Intermediates and Chemicals manufacturing plant and purchase of new machineries in MIDC
- Repayment/prepayment of all or certain of our borrowings availed of by our Company
- General corporate purposes
Financials
Profit & Loss
| Financial Year | FY26 |
|---|---|
| RevenueCr | 100 |
| Operating ProfitCr | 5 |
| OPM% | 4.7 |
| PBTCr | 6 |
| PATCr | 5 |
| EPS | 3 |
Balance Sheet
| Financial Year | FY26 |
|---|---|
| Equity CapitalCr | 20 |
| ReservesCr | 33 |
| BorrowingsCr | 37 |
| Total AssetsCr | 100 |
Cash Flow
| Financial Year | FY26 |
|---|---|
| Operating Cash FlowCr | -9 |
| Investing Cash FlowCr | -13 |
| Financing Cash FlowCr | 28 |
| Net Cash FlowCr | 6 |
Strengths & Risks
Strengths · as stated in the DRHP
- Strengthen our market position by increasing the long-term relationship with the clients.
- Comprehensive product portfolio.
- Streamlined supply chain management.
- Experienced management team with proven execution capabilities.
Strategies · as stated in the DRHP
- Invest in proposed manufacturing facility and enter into manufacturing segment.
Risks · as stated in the DRHP
- Our company is positioning itself to expand its market presence by diversifying into the manufacturing of Active Pharmaceutical Ingredients ("APIs"), which serve as raw materials for the formulation of various types of Finished Dosage Forms ("FDF") and Excipients. However, this expansion may expose us to several risks that could adversely affect our growth, prospects, cash flows, business operations, and financial condition.
- We may incur losses, and our reputation may be adversely affected if customers return our products due to the distribution of expired, unsafe, defective, ineffective, or counterfeit products, as well as product spoilage, breakage, or damage during transportation or storage. Failure to comply with customer-prescribed quality standards may also result in loss of business. In addition, we may be subject to product liability claims.
- We derive a significant portion of our revenue from customers located in Maharashtra. Any adverse developments in the region could adversely affect our business, results of operations, cash flows and financial condition.
- Our Company is reliant on the demand from the pharmaceutical industry for a significant portion of our revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage our sales could have an adverse impact on our Company's business and results of operations.
- Since our inception, we have completed one of the acquisitions of distributors in India to expand our business and increase our customer base and may continue to complete more acquisitions in the future. However, we may be unable to realize the anticipated benefits of past or future acquisitions successfully. Further, if we are unable to identify expansion opportunities or experience delays or other problems in implementing our strategy of inorganic growth, our business, financial condition, results of operations, cash flows and prospects may be adversely affected.
- We procure a significant portion of our raw materials from suppliers based in the State of Maharashtra. Any adverse developments in the region could adversely affect our business, results of operations, cash flows and financial condition.